SBRT for Oligometastatic Lymph Node Recurrence in Prostate Cancer: a Single Institution Experience

Predictive Factors for the Benefit of Stereotactic Body Radiotherapy for Oligometastatic Lymph Node Recurrence in Prostate Cancer: a Single Institution Experience

Single-institution retrospective analysis for predictive factors of prostate cancer patients presenting with isolated or limited lymph node (LN) recurrence (1-3 lesions) on F-Ccholine PET-CT (CholPET) treated with SBRT between January 2010 and July 2015.

Single-institution retrospective analysis of consecutive prostate cancer patients after definitive primary treatment, without local recurrence, presenting with isolated or limited lymph node (LN) recurrence (1-3 lesions) on F-Ccholine PET-CT (CholPET) treated with SBRT between January 2010 and July 2015.

Endpoints of interest are biochemical response rate (defined as a reduction by at least 10% of the initial PSA value), time to biochemical recurrence (TBR) (defined as the time interval from SBRT until second PSA rise), and time interval between SBRT and ADT start. Univariate analysis is used to identify prognostic factors.

Inclusion Criteria:

• histologically proven diagnosis of prostate cancer
• Radical prostatectomy (± salvage radiotherapy)
• PSA relapse (defined by two consecutive rising PSA values >0.2 ug/l)
• one to three lymphnodes positive on Choline-PET
• no recurrence in prostatic bed on Choline-PET
• WHO performance status of 0-1
• no previous chemotherapy or ADT for prostate cancer.

Exclusion Criteria:

• primary treatment for prostate cancer by RT or brachytherapy
• bone (M1b) metastases
• visceral (M1c) metastases
• any symptomatic nodal lesion